Acconeer yesterday announced a design win of over SEK 50m for access control related to a major Japa...
Redeye comments on Evaxion’s extreme share price movement yesterday.
XVIVO delivers a soft 12% organic growth in the last quarter of 2023 (based on CER excluding acquisi...
Redeye updates its estimates and valuation following Coala Life’s recent rights issue, securing cSEK...
We update our estimates ahead of Arise’s Q4 report on the back of the recently published production ...
Organic sales decline again... ...but strong margin and FCF development In good shape for eventual m...
Prel. Q4 figures: EE 3.7m, revenue SEK 37m, EBIT SEK 15.
Equity analyst Markus Almerud interviews Zwipe's CEO Robert Puskaric after the announcement that the...
Vitrolife provides an update ahead of the total Q4 due on 2 February.
Redeye comments on the presentation of updated data from the trial of fostrox in combination with Le...
Starts deploying its cash pile... ...and executing on M&A-focused growth strategy.
Q4 trading update in line '24e slightly down on lower oil price and production P/NAV of 0.
SEK 4.3bn impairment charge of Igenomix 1.6% beat on preliminary Q4 adj EBITDA Minor positive earnin...
Q4e: Clean EBIT of SEK -20m Pulp prices up and demand better Fair value range: SEK 9-16/sh Pulp bet...
Det svenska sensorteknikbolaget JonDeTech Sensors AB (”JonDeTech” eller ”Bolaget”) designar, produce...
Aptahem fyller på kassan via en företrädesemission vilken som högst kan inbringa ca 35 MSEK.
Redeye comments on the directed share issue that completes the previous rights issue.
Redeye updates its estimates ahead of the Q4 report (due 20 February).
Q4 report due 29 Feb Q4'23e net sales of SEK 464m, EBITA of SEK 59m We estimate the fair value at SE...
Q4 due on 20 February; we forecast -2% org. growth EBITA cut 1% on '24e-'25e because of FX 4.